Afficher la notice abrégée

Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab

dc.rights.licenseopenen_US
dc.contributor.authorFISSOLO, Nicolas
dc.contributor.authorPIGNOLET, Beatrice
dc.contributor.authorRIO, Jordi
dc.contributor.authorVERMERSCH, Patrick
hal.structure.identifierNeurocentre Magendie : Physiopathologie de la Plasticité Neuronale [U1215 Inserm - UB]
dc.contributor.authorRUET, Aurelie
dc.contributor.authorDESEZE, Jerome
dc.contributor.authorLABAUGE, Pierre
dc.contributor.authorVUKUSIC, Sandra
dc.contributor.authorPAPEIX, Caroline
dc.contributor.authorMARTINEZ-ALMOYNA, Laurent
dc.contributor.authorTOURBAH, Ayman
dc.contributor.authorCLAVELOU, Pierre
dc.contributor.authorMOREAU, Thibault
dc.contributor.authorPELLETIER, Jean
dc.contributor.authorLEBRUN-FRENAY, Christine
dc.contributor.authorBOURRE, Bertrand
dc.contributor.authorDEFER, Gilles
dc.contributor.authorMONTALBAN, Xavier
dc.contributor.authorBRASSAT, David
dc.contributor.authorCOMABELLA, Manuel
dc.date.accessioned2022-01-06T15:31:23Z
dc.date.available2022-01-06T15:31:23Z
dc.date.created2021
dc.date.issued2021-04-26
dc.identifier.issn2332-7812en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/124330
dc.description.abstractEnOBJECTIVES: The study aimed to assess the potential for serum neurofilament light chain (NFL) levels to predict the risk of progressive multifocal leukoencephalopathy (PML) in natalizumab (NTZ)-treated patients with multiple sclerosis (MS) and to discriminate PML from MS relapses. METHODS: NFL levels were measured with single molecule array (Simoa) in 4 cohorts: (1) a prospective cohort of patients with MS who developed PML under NTZ therapy (pre-PML) and non-PML NTZ-treated patients (NTZ-ctr) (2) a cohort of patients whose blood was collected during PML (3) an independent cohort of non-PML NTZ-treated patients with serum NFL determinations at 2 years (replication cohort) and (4) a cohort of patients whose blood was collected during exacerbations. RESULTS: Serum NFL levels were significantly increased after 2 years of NTZ treatment in pre-PML patients compared with NTZ-ctr. The prognostic performance of serum NFL levels to predict PML development at 2 years was similar in the NTZ-ctr group and replication cohort. Serum NFL levels also distinguished PML from MS relapses and were 8-fold higher during PML compared with relapses. CONCLUSIONS: These results support the use of serum NFL levels in clinical practice to identify patients with relapsing-remitting MS at higher PML risk and to differentiate PML from clinical relapses in NTZ-treated patients. CLASSIFICATION OF EVIDENCE: This study provides Class I evidence that serum NFL levels can identify NTZ-treated patients with MS who will develop PML with a sensitivity of 67% and specificity of 80%.
dc.language.isoENen_US
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/*
dc.title.enSerum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab
dc.title.alternativeNeurol Neuroimmunol Neuroinflamm.en_US
dc.typeArticle de revueen_US
dc.identifier.doi10.1212/NXI.0000000000001003en_US
dc.subject.halSciences du Vivant [q-bio]/Neurosciences [q-bio.NC]en_US
dc.identifier.pubmed33903203en_US
bordeaux.journalNeurologyen_US
bordeaux.volume8en_US
bordeaux.hal.laboratoriesNeurocentre Magendie - UMR-S 1215en_US
bordeaux.issue4en_US
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.exportfalse
dc.rights.ccCC BY-NC-NDen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Neurology&rft.date=2021-04-26&rft.volume=8&rft.issue=4&rft.eissn=2332-7812&rft.issn=2332-7812&rft.au=FISSOLO,%20Nicolas&PIGNOLET,%20Beatrice&RIO,%20Jordi&VERMERSCH,%20Patrick&RUET,%20Aurelie&rft.genre=article


Fichier(s) constituant ce document

Thumbnail
Nom:
license_rdf
Taille:
811octets
Format:
application/rdf+xml
Voir/Ouvrir
Thumbnail
Nom:
MAGENDIE_ NeurolNeuroimmunolNe ...
Taille:
448.3Ko
Format:
PDF
Voir/Ouvrir

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée